Article: PP20 Cost-effectiveness of Ibrutinib as Frontline Treatment For Adult Patients With Chronic Lymphocytic Leukaemia in Belgium

€3.03

SKU: product-article-14848 Category: General

Description
Reviews (0)

Description

PP20 Cost-effectiveness of Ibrutinib as Frontline Treatment For Adult Patients With Chronic Lymphocytic Leukaemia in Belgium

Reviews

There are no reviews yet.

Be the first to review “Article: PP20 Cost-effectiveness of Ibrutinib as Frontline Treatment For Adult Patients With Chronic Lymphocytic Leukaemia in Belgium”

You must be logged in to post a review.

Top

Article: PP20 Cost-effectiveness of Ibrutinib as Frontline Treatment For Adult Patients With Chronic Lymphocytic Leukaemia in Belgium

Description

Reviews

Related products

Article: Highlights in breast cancer

Article: Highlights in gynaecological cancers

Article: Highlights in respiratory oncology

Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma